Show simple item record

dc.contributor.authorPhelan, P J
dc.contributor.authorMoran, A-M
dc.contributor.authorO'Kelly, P
dc.contributor.authorHeng, P Y
dc.contributor.authorYussof, S M
dc.contributor.authorWalshe, J J
dc.contributor.authorMagee, C
dc.contributor.authorConlon, P J
dc.date.accessioned2012-02-01T10:02:17Z
dc.date.available2012-02-01T10:02:17Z
dc.date.issued2012-02-01T10:02:17Z
dc.identifier.citationIr J Med Sci. 2011 Jun;180(2):429-33. Epub 2010 Oct 29.en_GB
dc.identifier.issn1863-4362 (Electronic)en_GB
dc.identifier.issn0021-1265 (Linking)en_GB
dc.identifier.pmid21046471en_GB
dc.identifier.doi10.1007/s11845-010-0626-8en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207220
dc.description.abstractBACKGROUND: Steroid therapy is associated with significant morbidity in renal transplant recipients. However, there is concern that steroid withdrawal will adversely affect outcome. METHODS: We report on 241 renal transplant recipients on different doses of corticosteroids at 3 months (zero, 5 mg/day). Parameters analysed included blood pressure, lipid profile, weight change, new onset diabetes after transplantation (NODAT), allograft survival and acute rejection. RESULTS: Elimination of corticosteroids had no impact on allograft survival at 1 year. There were no cases of NODAT in the steroid withdrawal group compared with over 7% in each of the steroid groups. There were no significant improvements in weight gain, blood pressure control or total cholesterol with withdrawal of steroids before 3 months. CONCLUSIONS: In renal transplant patients treated with tacrolimus and mycophenolate, early withdrawal of steroids does not appear to adversely affect allograft outcome at 1 year. It may result in less NODAT.
dc.language.isoengen_GB
dc.subject.meshAdrenal Cortex Hormones/*administration & dosage/adverse effectsen_GB
dc.subject.meshAdulten_GB
dc.subject.meshDiabetes Mellitus/etiologyen_GB
dc.subject.meshDrug Therapy, Combinationen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshFollow-Up Studiesen_GB
dc.subject.mesh*Graft Survivalen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunosuppressive Agents/therapeutic useen_GB
dc.subject.meshIrelanden_GB
dc.subject.meshKidney Transplantation/*immunologyen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshMycophenolic Acid/analogs & derivatives/therapeutic useen_GB
dc.subject.meshRetrospective Studiesen_GB
dc.subject.meshTacrolimus/therapeutic useen_GB
dc.subject.meshYoung Adulten_GB
dc.titleSteroid withdrawal in renal transplant patients: the Irish experience.en_GB
dc.contributor.departmentDepartment of Nephrology, Beaumont Hospital, Dublin 9, Ireland., paulphel@gmail.comen_GB
dc.identifier.journalIrish journal of medical scienceen_GB
dc.description.provinceLeinster
html.description.abstractBACKGROUND: Steroid therapy is associated with significant morbidity in renal transplant recipients. However, there is concern that steroid withdrawal will adversely affect outcome. METHODS: We report on 241 renal transplant recipients on different doses of corticosteroids at 3 months (zero, </= 5 mg/day, > 5 mg/day). Parameters analysed included blood pressure, lipid profile, weight change, new onset diabetes after transplantation (NODAT), allograft survival and acute rejection. RESULTS: Elimination of corticosteroids had no impact on allograft survival at 1 year. There were no cases of NODAT in the steroid withdrawal group compared with over 7% in each of the steroid groups. There were no significant improvements in weight gain, blood pressure control or total cholesterol with withdrawal of steroids before 3 months. CONCLUSIONS: In renal transplant patients treated with tacrolimus and mycophenolate, early withdrawal of steroids does not appear to adversely affect allograft outcome at 1 year. It may result in less NODAT.


This item appears in the following Collection(s)

Show simple item record